{ "schemaVersion": 2, "eyebrow": "Hepatology", "title": "Hepatic Encephalopathy", "summary": "Manage suspected hepatic encephalopathy as a clinical diagnosis of exclusion: stabilize impaired consciousness, grade overt disease, identify reversible precipitants and shunts, initiate bowel-directed therapy, and use recurrence or TIPS risk to drive secondary prevention and transplant-focused planning.", "seoDescription": "Physician guide to diagnosing, grading, treating, and preventing hepatic encephalopathy in cirrhosis, including covert disease and TIPS risk.", "clinicalQuestion": "How should clinicians diagnose, treat, prevent, and escalate care for hepatic encephalopathy in chronic liver disease?", "specialty": "Hepatology", "audience": "U.S. physicians and medical trainees", "tags": [ "hepatic encephalopathy", "cirrhosis", "lactulose", "rifaximin", "West Haven criteria", "covert hepatic encephalopathy", "TIPS" ], "keyTakeaways": [ "Diagnose hepatic encephalopathy clinically only after excluding competing causes of brain dysfunction; grade overt disease with West Haven criteria and Glasgow Coma Scale when consciousness is impaired.[23][24]", "In overt hepatic encephalopathy, search for and correct precipitants while initiating lactulose titrated to bowel response; lactulose is first-line therapy for symptomatic disease.[21][23][24]", "Add rifaximin for prevention of recurrent hepatic encephalopathy; the commonly used regimen is 550 mg orally twice daily, generally with lactulose rather than as monotherapy.[19][8]", "Before elective TIPS, screen for both overt and covert hepatic encephalopathy; covert disease is a relative contraindication and should alter procedural selection or technique.[3][5]", "An overt hepatic encephalopathy episode marks decompensated cirrhosis and carries adverse prognostic significance, warranting reassessment of liver-directed and transplant-oriented management.[14][2]" ], "sections": [ { "id": "initial-assessment-and-triage", "eyebrow": "Immediate assessment", "heading": "Triage altered mental status before attributing it to hepatic encephalopathy", "intro": "Treat HE as a diagnosis of exclusion, not as a laboratory diagnosis.", "paragraphs": [ "In a patient with cirrhosis or known portosystemic shunting and altered cognition, first determine whether reduced consciousness compromises airway protection or requires a monitored setting. Grade overt HE clinically with West Haven criteria (WHC) and, when consciousness is impaired, the Glasgow Coma Scale; WHC grade 3 is somnolence with gross disorientation, whereas grade 4 is coma.[1][23][24]", "Do not label all encephalopathy in cirrhosis as HE. The AASLD/EASL framework requires exclusion of other causes of brain dysfunction; pursue an alternate neurologic, toxic-metabolic, infectious, or structural diagnosis when the presentation is focal, abrupt without a hepatic context, disproportionate to known liver disease, or fails to improve after precipitant correction and HE-directed treatment.[23][24][15]", "Classify the clinical setting because it changes the next action: HE can result from liver insufficiency, portosystemic shunting, or both. Overt HE in cirrhosis defines decompensation; recurrent episodes despite optimized medical therapy should prompt review for a large spontaneous portosystemic shunt, TIPS-associated shunting, and suitability for liver transplantation.[14][12]" ], "bullets": [ "WHC 0: normal examination; psychomotor impairment, if present, is minimal HE. WHC 1: reduced awareness and attention with mild asterixis or tremor.[1]", "WHC 2: lethargy, disorientation, inappropriate behavior, obvious asterixis, or slurred speech.[1]", "WHC 3–4: somnolence to coma; prioritize airway and monitored care while treating likely HE and competing diagnoses.[1][23]" ], "subsections": [], "table": { "caption": "Clinical severity categories direct supervision and diagnostic urgency.[1][23][24]", "columns": [ "Clinical category", "Bedside findings", "Immediate implication" ], "rows": [ [ "Covert HE", "No obvious disorientation; abnormal psychometric or neurophysiologic testing may identify impairment.[1][23]", "Assess functional consequences and use validated testing rather than WHC alone.[23][24]" ], [ "Overt HE, WHC 1–2", "Attention impairment, lethargy, disorientation, asterixis, behavioral change, or slurred speech.[1]", "Identify precipitating illness and begin bowel-directed therapy.[21][23]" ], [ "Overt HE, WHC 3–4", "Somnolence with gross disorientation or coma.[1]", "Escalate monitoring and airway assessment; evaluate competing causes in parallel.[23][24]" ] ] } }, { "id": "diagnostic-workup", "eyebrow": "Diagnostic branch point", "heading": "Confirm the hepatic context and actively identify reversible precipitants", "intro": "The practical diagnostic task is to distinguish HE from another encephalopathy and find the event sustaining it.", "paragraphs": [ "Establish whether the patient has advanced liver disease, portal hypertension, or a portosystemic shunt. HE is defined as brain dysfunction caused by liver insufficiency and/or portosystemic shunting, and overt HE can occur even without cirrhosis when extensive portosystemic shunting is present.[12][14]", "Perform a directed precipitant evaluation at each overt episode. Infection, renal dysfunction, hyponatremia, diabetes-related metabolic disturbance, and older age can contribute to cognitive dysfunction or increase susceptibility to HE; their presence should trigger correction of the abnormality and reassessment rather than escalation of ammonia-lowering therapy alone.[15]", "Use neuroimaging selectively to evaluate suspected structural disease rather than to establish HE. CT has poor sensitivity for cerebral edema, and structural brain MRI has no validated role as a cognitive test for HE; imaging is therefore most useful when examination or course suggests an alternate intracranial process.[4]", "If recurrent HE persists after treatment of precipitating illness and adherence review, evaluate for a major spontaneous portosystemic shunt or problematic TIPS physiology. Shunt embolization has been used for refractory HE associated with large spontaneous portosystemic shunts, while recurrent HE also strengthens the rationale for transplant-directed evaluation in advanced liver disease.[10][14]" ], "bullets": [ "Reassess medications and exposures whenever cognition changes; HE remains a diagnosis of exclusion even in established cirrhosis.[23][24]", "Correct reversible metabolic contributors, including renal dysfunction and hyponatremia, before concluding that persistent symptoms represent treatment-refractory HE.[15]", "Escalate structural neurologic evaluation when focal deficits, atypical trajectory, or absent response to HE-directed management raises concern for a non-HE diagnosis.[23][24][4]" ], "subsections": [], "table": { "caption": "Workup findings should change the working diagnosis or the immediate corrective action.[14][15][23][24]", "columns": [ "Finding", "Interpretation", "Action" ], "rows": [ [ "Known cirrhosis or portal hypertension with compatible cognitive change", "Supports HE but does not exclude another encephalopathy.[23][24]", "Grade clinically, investigate precipitants, and begin treatment when overt HE is likely.[21][23]" ], [ "Extensive portosystemic shunt with or without cirrhosis", "May be the principal driver of HE.[14]", "Review shunt anatomy and consider shunt-directed management in refractory disease.[10][14]" ], [ "Infection, renal dysfunction, hyponatremia, or metabolic comorbidity", "Can precipitate or mimic cognitive impairment in cirrhosis.[15]", "Treat the identified condition and reassess mental status before escalating chronic therapy.[15]" ], [ "Focal neurologic findings or atypical nonresponse", "Raises concern for an alternative brain disorder; HE cannot be assumed.[23][24]", "Pursue targeted neurologic evaluation and imaging as clinically indicated.[4][23]" ] ] } }, { "id": "treatment-of-overt-he", "eyebrow": "Acute treatment", "heading": "Treat overt hepatic encephalopathy while correcting the trigger", "intro": "Acute therapy should run concurrently with management of the precipitating condition.", "paragraphs": [ "Use lactulose as first-line treatment for symptomatic overt HE and titrate administration to bowel response; a practical target described in clinical use is 2–3 loose stools daily. Reassess hydration status, adherence, stool output, cognition, and the continuing precipitant rather than assuming nonresponse reflects inadequate dose alone.[21][19]", "For hospitalized or severe presentations, deliver therapy by the route compatible with mental status and aspiration risk, while airway protection and monitored care take priority in WHC grade 3–4 disease. The treatment endpoint is improvement in cognition and function after correction of reversible drivers, not normalization of a single laboratory marker.[1][21][23]", "Polyethylene glycol 3350-electrolyte solution has been studied against lactulose for overt HE, including in the HELP randomized trial, but lactulose and rifaximin remain the preferred therapies in current management discussions. Consider this evidence as an alternative cathartic strategy only within an individualized inpatient plan rather than replacing standard recurrence prevention.[10][22]", "L-ornithine L-aspartate has trial data in HE, but comparative evidence is limited by substantial inclusion of minimal HE and inadequate evidence in severe overt HE. Do not substitute it for lactulose-based first-line management when treating a clinically significant overt episode.[11][21]" ], "bullets": [ "Document WHC and functional status before therapy; repeat bedside assessment after bowel response and precipitant treatment to establish trajectory.[1][23]", "If mental status does not improve, reopen the differential diagnosis and seek persistent infection, metabolic derangement, medication effect, or shunt-related HE.[15][23][24]", "Avoid using improvement after empiric therapy as the sole proof of HE; the diagnosis remains exclusionary.[23][24]" ], "subsections": [], "table": { "caption": "Therapy selection in overt HE should be coupled to serial neurologic assessment and precipitant management.[1][19][21][23]", "columns": [ "Clinical situation", "Treatment action", "Monitoring or escalation" ], "rows": [ [ "Symptomatic overt HE with intact airway", "Start lactulose and titrate to 2–3 loose stools daily.[19][21]", "Track stool output, hydration, mental status, and correction of precipitants.[15][19]" ], [ "WHC 3–4 or impaired airway protection", "Provide monitored care and address airway risk while administering feasible HE therapy.[1][23]", "Use repeated WHC/GCS assessment and investigate non-HE causes concurrently.[23][24]" ], [ "Persistent encephalopathy despite initial therapy", "Reassess diagnosis, ongoing precipitant, medication adherence, and portosystemic shunting.[14][15][23]", "Consider shunt-directed and transplant-focused evaluation when recurrent or refractory.[10][14]" ] ] } }, { "id": "secondary-prevention-and-covert-he", "eyebrow": "Long-term management", "heading": "Prevent recurrence and test covert disease when the result will change function or procedural decisions", "intro": "Recurrence prevention depends on lactulose adherence, risk reassessment, and selective rifaximin use.", "paragraphs": [ "After an overt HE episode, maintain lactulose with titration guided by stool response and educate caregivers to recognize underuse, overtreatment, dehydration, and recurrent cognitive change. Inappropriate lactulose use and lack of education have been associated with preventable readmissions; a 2–3 loose stool daily target is commonly used for outpatient titration.[19][21]", "For recurrent HE prevention, use rifaximin 550 mg orally twice daily in conjunction with lactulose. Rifaximin is widely used to maintain remission and reduces recurrence, but it is not established as routine monotherapy for prevention; emerging evidence also raises antimicrobial-resistance concerns that should be weighed during prolonged treatment.[19][8]", "Covert HE requires formal testing rather than bedside impression alone. PHES is a well-validated psychometric tool; guideline-oriented TIPS screening recommends at least two of PHES, Stroop testing, critical flicker frequency, and spectral-enhanced or quantitative EEG. Treatment may be considered when covert impairment compromises quality of life or creates safety and functional concern.[3][20][12]", "Do not assume that all cognitive impairment in a patient with cirrhosis is covert HE. Diabetes, renal dysfunction, infection, hyponatremia, neurologic disease, thiamine-related dysfunction, and aging complicate interpretation and may require correction or separate evaluation before assigning persistent impairment to HE.[15]" ], "bullets": [ "Rifaximin regimen for recurrence prevention: 550 mg orally twice daily, generally added to lactulose.[19][8]", "For suspected covert HE, select validated psychometric or neurophysiologic testing when a positive result would alter driving, occupational counseling, caregiver planning, or TIPS candidacy.[3][20]", "Recurrent HE despite adherent lactulose-rifaximin therapy should trigger assessment for a large spontaneous shunt or TIPS-related HE rather than indefinite empiric medication escalation.[10][14]" ], "subsections": [], "table": { "caption": "Covert HE testing is most useful when it changes functional counseling or an invasive portal-hypertension decision.[3][20]", "columns": [ "Use case", "Testing approach", "What an abnormal result changes" ], "rows": [ [ "Suspected covert HE affecting daily function", "Use PHES or another validated psychometric/neurophysiologic assessment.[3][20]", "Supports targeted treatment consideration when quality of life or overt-HE risk is a concern.[20][12]" ], [ "Pre-elective TIPS assessment", "Use at least two of PHES, Stroop testing, critical flicker frequency, and spectral-enhanced or quantitative EEG.[3][5]", "Covert HE is a relative contraindication and should modify the TIPS risk-benefit decision.[3][5]" ], [ "Normal PHES before TIPS for refractory ascites", "Normal PHES identifies lower post-procedure HE risk in reported prospective data.[3]", "A 90% probability of remaining HE-free after TIPS was reported in this subgroup.[3]" ] ] } }, { "id": "treatment-escalation-and-prognosis", "eyebrow": "Procedural and prognostic decisions", "heading": "Use HE history to reconsider TIPS, shunt anatomy, and transplant trajectory", "intro": "HE changes the balance between portal-hypertension control and neurologic risk.", "paragraphs": [ "Screen all patients being considered for elective TIPS for both overt and covert HE because TIPS can precipitate or worsen encephalopathy. Evidence of covert HE is a relative contraindication, and age older than 65 years should increase caution even though it is not an absolute contraindication.[3][5]", "When a patient has refractory ascites and a normal PHES, reported data suggest a 90% probability of remaining free of HE after TIPS; this is a risk-stratification observation, not a substitute for global assessment of procedural benefit and liver reserve.[3]", "For recurrent or refractory HE with a large spontaneous portosystemic shunt, discuss shunt embolization in a multidisciplinary liver setting. This approach has reported safety and efficacy in a multicenter survey, but selection must account for the competing portal-hypertension consequences of reducing shunt flow.[10]", "An overt HE event is a poor prognostic marker. Overt HE occurs in approximately 20% of patients with cirrhosis each year, and one review reported 23% survival at 3 years after onset; HE severity is also associated with short-term mortality independently of extrahepatic organ failure and with 90-day waitlist mortality independently of MELD.[2][13]" ], "bullets": [ "Before elective TIPS: document overt HE history and perform formal covert HE screening with at least two recommended modalities where feasible.[3][5]", "After TIPS: new or worsening encephalopathy should prompt assessment for post-TIPS HE and review of other precipitants rather than attribution to baseline cirrhosis alone.[3][5]", "After overt HE: reassess candidacy and timing for transplant-focused care because the episode signals decompensated disease and adverse prognosis.[14][2][13]" ], "subsections": [], "table": { "caption": "Procedural decisions require explicit balancing of portal-hypertension benefit against HE risk.[3][5][10]", "columns": [ "Decision", "HE-specific factor", "Next action" ], "rows": [ [ "Elective TIPS", "Covert or overt HE increases concern for post-TIPS encephalopathy.[3][5]", "Perform formal screening; reconsider elective TIPS when covert HE is present unless risk-mitigation strategies justify proceeding.[3][5]" ], [ "Refractory HE with large spontaneous shunt", "Shunt flow may be driving persistent neurocognitive dysfunction.[10][14]", "Review candidacy for shunt embolization with liver and interventional teams.[10]" ], [ "Recurrent overt HE", "Defines decompensated cirrhosis and indicates poor prognosis.[14][2]", "Advance transplant-oriented evaluation alongside recurrence prevention.[14][13]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "[PDF] 22-554 CROSS DISCIPLINE TEAM LEADER REVIEW", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000CrossR.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 2, "title": "Hepatic encephalopathy due to liver cirrhosis", "detail": "www.bmj.com", "url": "https://www.bmj.com/content/351/bmj.h4187", "authors": "www.bmj.com", "host": "www.bmj.com" }, { "number": 3, "title": "Transjugular intrahepatic portosystemic stent-shunt in the ... - Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/69/7/1173", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 4, "title": "Hepatic encephalopathy: Part 1, a diagnostic approach", "detail": "fg.bmj.com", "url": "https://fg.bmj.com/content/flgastro/17/4/331.full.pdf", "authors": "fg.bmj.com", "host": "fg.bmj.com" }, { "number": 5, "title": "shunt in the management of portal hypertension - Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/gutjnl/69/7/1173.full.pdf", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 6, "title": "Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial) | BMJ Open Gastroenterolog...", "detail": "bmjopengastro.bmj.com", "url": "https://bmjopengastro.bmj.com/content/7/1/e000531", "authors": "bmjopengastro.bmj.com", "host": "bmjopengastro.bmj.com" }, { "number": 7, "title": "Probiotics for Secondary Prevention of Hepatic Encephalopathy? | NEJM Clinician", "detail": "clinician.nejm.org", "url": "https://clinician.nejm.org/probiotics-secondary-prevention-hepatic-encephalopathy-nejm-jw.NA36530", "authors": "clinician.nejm.org", "host": "clinician.nejm.org" }, { "number": 8, "title": "Increased risk of antimicrobial resistance in patients with cirrhosis and hepatic encephalopathy using rifaximin | Nature Communications", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-025-67326-y", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 9, "title": "Portosystemic shunt placement reveals blood signatures for the development of hepatic encephalopathy through mass spectrometry | Nature Communications", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-023-40741-9", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 10, "title": "Optimizing the liver transplant candidate | npj Gut and Liver - Nature", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s44355-024-00003-x", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 11, "title": "Intravenous versus oral ‘l-ornithine-l-aspartate’ in overt hepatic encephalopathy: a randomized comparative study | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-024-62293-8", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 12, "title": "Hepatic Encephalopathy: Diagnosis and Treatment in Advanced Liver Disease - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0899588522000387", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 13, "title": "Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF) - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S159086581831274X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 14, "title": "Hepatic encephalopathy in chronic liver disease: 2014... : Hepatology", "detail": "journals.lww.com", "url": "https://journals.lww.com/hep/fulltext/2014/08000/hepatic_encephalopathy_in_chronic_liver_disease_.30.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 15, "title": "Minimal/Covert Hepatic Encephalopathy – Impact of Comorbid Conditions - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0973688318306637", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 16, "title": "Hepatic encephalopathy in chronic liver disease:... : Hepatology", "detail": "journals.lww.com", "url": "https://journals.lww.com/hep/fulltext/10.1002/hep.27210~hepatic-encephalopathy-in-chronic-liver-disease-2014", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 17, "title": "Hepatic encephalopathy in chronic liver disease: 2014 Practice ...", "detail": "aasldpubs.onlinelibrary.wiley.com", "url": "https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.27210?e-page-2e4fdd4=20&e-page-92a6feb=16&e-page-91fcdc6=8&e-page-c0206ed=68&e-page-b4f3451=36&e-page-358fab5=11&term=perguntas&PageSpeed=noscript", "authors": "aasldpubs.onlinelibrary.wiley.com", "host": "aasldpubs.onlinelibrary.wiley.com" }, { "number": 18, "title": "Covert and Overt Hepatic Encephalopathy: Diagnosis and ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S1542356515009179", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 19, "title": "Retrospective cross‐sectional pilot study of rifaximin dosing for the prevention of recurrent hepatic encephalopathy - Lyon - 2017 - Journal of Gastroenterology and Hepatology - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.13759", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 20, "title": "Diagnosis and management of hepatic encephalopathy : Liver ...", "detail": "journals.lww.com", "url": "https://journals.lww.com/00137700-202304000-00002", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 21, "title": "Management of Overt Hepatic Encephalopathy - Lippincott", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/fulltext/00000434-201710001-00928~management-of-overt-hepatic-encephalopathy-a-retrospective", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 22, "title": "Advances in the management of complications from cirrhosis", "detail": "academic.oup.com", "url": "https://academic.oup.com/gastro/article/doi/10.1093/gastro/goae072/7727525", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 23, "title": "[PDF] Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice ...", "detail": "www.aasld.org", "url": "https://www.aasld.org/sites/default/files/2022-07/Hepatic%20Encephalopathy%20in%20Chronic%20Liver%20Disease%202014.pdf", "authors": "www.aasld.org", "host": "www.aasld.org" }, { "number": 24, "title": "Hepatic Encephalopathy in Chronic Liver Disease 2014. ...", "detail": "www.aasld.org", "url": "https://www.aasld.org/sites/default/files/2022-07/Hepatic Encephalopathy in Chronic Liver Disease 2014.pdf", "authors": "www.aasld.org", "host": "www.aasld.org" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "[PDF] 22-554 CROSS DISCIPLINE TEAM LEADER REVIEW", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000CrossR.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "validated outside the U.S. The ICT has been validated in a selected U.S. population and is freely downloadable at www.hecme.tv. RBANS is a test battery that has U.S. normative data but it has not been validated for the diagnosis of MHE in the U.S. This battery requires a psychologist for procurement", "score": 0.529191 }, { "number": 2, "title": "Hepatic encephalopathy due to liver cirrhosis", "detail": "www.bmj.com", "url": "https://www.bmj.com/content/351/bmj.h4187", "authors": "www.bmj.com", "host": "www.bmj.com", "snippet": "Title: Hepatic encephalopathy due to liver cirrhosis\n* Username * Password * Forgot your log in details? BMA Member Log In Log in via OpenAthens Log in via your institution. * Hepatic encephalopathy is a sign of poor prognosis and correlates with mortality in both in patients with acute live", "score": 0.8286204 }, { "number": 3, "title": "Transjugular intrahepatic portosystemic stent-shunt in the ... - Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/69/7/1173", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "Psychometric hepatic encephalopathy score (PHES) psychometric testing is a well validated tool for establishing the presence of encephalopathy, both covert and overt.139 This technique has been studied prospectively, is readily available and utility confirmed.140 A patient with refractory ascites wi", "score": 0.38671768 }, { "number": 4, "title": "Hepatic encephalopathy: Part 1, a diagnostic approach", "detail": "fg.bmj.com", "url": "https://fg.bmj.com/content/flgastro/17/4/331.full.pdf", "authors": "fg.bmj.com", "host": "fg.bmj.com", "snippet": "CT brain imaging has poor sensitivity for detecting cerebral oedema, Currently, structural brain MRI does not provide any validated cognitive", "score": 0.3168769 }, { "number": 5, "title": "shunt in the management of portal hypertension - Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/gutjnl/69/7/1173.full.pdf", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "Screening should ideally be at least two of the following: psychometric hepatic encephalopathy score (PHES) testing,", "score": 0.2653993 }, { "number": 6, "title": "Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial) | BMJ Open Gastroenterolog...", "detail": "bmjopengastro.bmj.com", "url": "https://bmjopengastro.bmj.com/content/7/1/e000531", "authors": "bmjopengastro.bmj.com", "host": "bmjopengastro.bmj.com", "snippet": "tle: Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial) | BMJ Open Gastroente", "score": 0.6636041 }, { "number": 7, "title": "Probiotics for Secondary Prevention of Hepatic Encephalopathy? | NEJM Clinician", "detail": "clinician.nejm.org", "url": "https://clinician.nejm.org/probiotics-secondary-prevention-hepatic-encephalopathy-nejm-jw.NA36530", "authors": "clinician.nejm.org", "host": "clinician.nejm.org", "snippet": "Probiotics for Secondary Prevention of Hepatic Encephalopathy? | NEJM Clinician\n\nJournal Watch\n\n# Probiotics for Secondary Prevention of Hepatic Encephalopathy?\n\nAtif Zaman, MD, MPH\n\nAtif Zaman, MD, MPH\n\nDec 18, 2014\n\nAtif Zaman, MD, MPH\n\nAtif Zaman, MD, MPH\n\nDecember 18, 2014\n\nAtif Zaman, MD, MPH\n\n", "score": 0.5158888 }, { "number": 8, "title": "Increased risk of antimicrobial resistance in patients with cirrhosis and hepatic encephalopathy using rifaximin | Nature Communications", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-025-67326-y", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "of 60, this effect of rifaximin is clinically meaningful considering the widespread global use of rifaximin. Such evidence is crucially needed to re-evaluate current treatment strategies for recurrent HE and prophylaxis management. Emerging alternatives for HE management, including fecal microbiota ", "score": 0.7382357 }, { "number": 9, "title": "Portosystemic shunt placement reveals blood signatures for the development of hepatic encephalopathy through mass spectrometry | Nature Communications", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-023-40741-9", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "(2016).\"). These drugs affect the composition of the gut microbiome, thus implicating microbial metabolites or products as potential agents that can influence the onset of HE– an observation supported by fecal microbiota transplant studies1.\"),75 in hepatic encephalopathy. Nutrients 13, 1–15 (2021).", "score": 0.5637388 }, { "number": 10, "title": "Optimizing the liver transplant candidate | npj Gut and Liver - Nature", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s44355-024-00003-x", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \nPubMed \nGoogle Scholar\n\nLaleman, W. et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 57, 2448–2457 (2013).\n\nArticle \nPubMed \nGoogle Scholar\n\nBajaj, J. S. et al. Fecal microbiota trans", "score": 0.5617203 }, { "number": 11, "title": "Intravenous versus oral ‘l-ornithine-l-aspartate’ in overt hepatic encephalopathy: a randomized comparative study | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-024-62293-8", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \nCAS \nPubMed \nGoogle Scholar\n\nSharma, K. et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial. Saudi J. Gastroenterol. 20(4), 225–232 (2014).\n\nArticle \nPubMed \nPubMed Central \nGoogle Scholar\n\nMittal, V. V., Sharm", "score": 0.528753 }, { "number": 12, "title": "Hepatic Encephalopathy: Diagnosis and Treatment in Advanced Liver Disease - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0899588522000387", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Hepatic Encephalopathy: Diagnosis and Treatment in Advanced Liver Disease - ScienceDirect\n# Hepatic Encephalopathy: Diagnosis and Treatment in Advanced Liver Disease. Hepatic encephalopathy is a major complication of advanced liver disease. Eighty percent of individuals with cirrhosis have mi", "score": 0.8430832 }, { "number": 13, "title": "Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF) - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S159086581831274X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "# Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). A 2014 joint clinical practice guideline of the European Association for the Study of the Liver and the American Association for the Study of Liver Disease concluded that minima", "score": 0.8235701 }, { "number": 14, "title": "Hepatic encephalopathy in chronic liver disease: 2014... : Hepatology", "detail": "journals.lww.com", "url": "https://journals.lww.com/hep/fulltext/2014/08000/hepatic_encephalopathy_in_chronic_liver_disease_.30.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "_Abbreviations:_ AASLD;American Association for the Study of Liver Diseases; ACLF;acute-on-chronic liver failure; ALD;alcoholic liver disease; ALF;acute liver failure; BCAAs;branced-chain amino acids; CFF;Critical Flicker Frequency; CHE;covert HE; CLD;chronic liver disease; CRT;Continuous Reaction T", "score": 0.8127637 }, { "number": 15, "title": "Minimal/Covert Hepatic Encephalopathy – Impact of Comorbid Conditions - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0973688318306637", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Minimal/Covert Hepatic Encephalopathy – Impact of Comorbid Conditions - ScienceDirect\n# Review Article Minimal/Covert Hepatic Encephalopathy – Impact of Comorbid Conditions. Mild cognitive dysfunction as in minimal or covert hepatic encephalopathy (HE) can be found in a variety of metabolic d", "score": 0.81025416 }, { "number": 16, "title": "Hepatic encephalopathy in chronic liver disease:... : Hepatology", "detail": "journals.lww.com", "url": "https://journals.lww.com/hep/fulltext/10.1002/hep.27210~hepatic-encephalopathy-in-chronic-liver-disease-2014", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Hepatology\nAASLD\n\nCrossmark: Check for updates\n\n# Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver\n\nThe AASLD/EASL Practice Guideline Subcommittee on Hepatic En", "score": 0.6991933 }, { "number": 17, "title": "Hepatic encephalopathy in chronic liver disease: 2014 Practice ...", "detail": "aasldpubs.onlinelibrary.wiley.com", "url": "https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.27210?e-page-2e4fdd4=20&e-page-92a6feb=16&e-page-91fcdc6=8&e-page-c0206ed=68&e-page-b4f3451=36&e-page-358fab5=11&term=perguntas&PageSpeed=noscript", "authors": "aasldpubs.onlinelibrary.wiley.com", "host": "aasldpubs.onlinelibrary.wiley.com", "snippet": "These recommendations provide a data-supported approach. They are based on the following: (1) formal review and analysis of the recently published world", "score": 0.45057756 }, { "number": 18, "title": "Covert and Overt Hepatic Encephalopathy: Diagnosis and ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S1542356515009179", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "WHC West Haven criteria Hepatic encephalopathy (HE) is a prevalent complication of portal hypertension and cirrhosis that is seen in 50% to 70% of patients.1", "score": 0.69672287 }, { "number": 19, "title": "Retrospective cross‐sectional pilot study of rifaximin dosing for the prevention of recurrent hepatic encephalopathy - Lyon - 2017 - Journal of Gastroenterology and Hepatology - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.13759", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "The study purpose was to determine efficacy of traditional rifaximin dosing (400 mg three times daily) compared with newer dosing (550 mg twice daily) via readmission rates for the prevention of recurrent HE. The rifaximin 550-mg dosing strategy should be utilized in hospitalized patients for the pr", "score": 0.6296157 }, { "number": 20, "title": "Diagnosis and management of hepatic encephalopathy : Liver ...", "detail": "journals.lww.com", "url": "https://journals.lww.com/00137700-202304000-00002", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "We suggest treating all covert HE patients with lactulose or rifaximin to improve quality of life and reduce the risk of overt HE. Grade 2+, Strong Agreement.", "score": 0.6211049 }, { "number": 21, "title": "Management of Overt Hepatic Encephalopathy - Lippincott", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/fulltext/00000434-201710001-00928~management-of-overt-hepatic-encephalopathy-a-retrospective", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Lactulose is the current first line treatment method for symptomatic patients, with titration to bowel movement as the most effective method of determining", "score": 0.58919704 }, { "number": 22, "title": "Advances in the management of complications from cirrhosis", "detail": "academic.oup.com", "url": "https://academic.oup.com/gastro/article/doi/10.1093/gastro/goae072/7727525", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "While lactulose and rifaximin are the preferred treatments for hepatic encephalopathy, many alternative treatment options may be used in", "score": 0.50446826 }, { "number": 23, "title": "[PDF] Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice ...", "detail": "www.aasld.org", "url": "https://www.aasld.org/sites/default/files/2022-07/Hepatic%20Encephalopathy%20in%20Chronic%20Liver%20Disease%202014.pdf", "authors": "www.aasld.org", "host": "www.aasld.org", "snippet": "53 FULL TEXT REFERENCES RECOMMENDATIONS WEB SITE CONTENTS Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by AASLD and EASL AASLD PRACTICE GUIDELINE FULL TEXT RECOMMENDATIONS: 3. Hepatic encephalopathy should be treated as a continuum ranging from unimpaired cognitive functi", "score": 0.7845341 }, { "number": 24, "title": "Hepatic Encephalopathy in Chronic Liver Disease 2014. ...", "detail": "www.aasld.org", "url": "https://www.aasld.org/sites/default/files/2022-07/Hepatic Encephalopathy in Chronic Liver Disease 2014.pdf", "authors": "www.aasld.org", "host": "www.aasld.org", "snippet": "53 FULL TEXT REFERENCES RECOMMENDATIONS WEB SITE CONTENTS Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by AASLD and EASL AASLD PRACTICE GUIDELINE FULL TEXT RECOMMENDATIONS: 3. Hepatic encephalopathy should be treated as a continuum ranging from unimpaired cognitive functi", "score": 0.7813477 } ], "publishedAt": "2026-09-16T01:03:06.661456+00:00", "updatedAt": "2026-09-16T01:03:06.661456+00:00", "readingMinutes": 6, "slug": "hepatic-encephalopathy" }